Patents recently issued in the US and allowed in Japan provide additional coverage for the company’s proprietary SETTM technologies for patients with HR+HER2- breast cancer and strengthens the company’s intellectual property portfolio.
Houston, TX, September 22, 2022 – Delphi DiagnosticsTM Inc. today announced that the United States Patent and Trademark Office has issued US11,459,617 on October 4, 2022, covering the Sensitivity to Endocrine Therapy (SETER/PR) Test through 2037. The patent was also recently allowed in Japan. A patent for SET has already been granted in the European Union and is pending in other commercially relevant jurisdictions. The granting of this new patent titled, “Targeted measure of transcriptional activity related to hormone receptors,” strengthens the company’s Intellectual property portfolio. Delphi Diagnostics holds an exclusive license from The University of Texas MD Anderson Cancer Center in Houston, TX, to commercialize the SET technology developed by the laboratory of Dr. W. Fraser Symmans1.
The SETER/PR Test measures the activity of the most important biological process in the majority of breast cancers, i.e. breast cancers that express estrogen and/or progesterone hormone receptors. Clinical studies that have been published and/or recently presented at major medical meetings have demonstrated its independent contribution to risk assessment and prediction of treatment benefits.
“This newly issued patent is an important step in further establishing the novel intellectual property behind our SET technology,” stated Delphi Diagnostics Chief Executive Officer Winz Casagrande. “We are committed to bringing the SET test to as many breast cancer patients and their healthcare providers as possible so that the valuable information from this test can help tailor the patient’s treatment plan for the selection, order, dosage, and duration of therapeutics.”
1Dr. Symmans has a personal financial relationship with Delphi that has been identified as a conflict of interest and is managed by MD Anderson’s Conflict of Interest Committee.
About Delphi Diagnostics
Delphi Diagnostics Inc. is a Texas-based company focused on advancing clinically valid tests for prognosis and prediction of breast cancer treatment. The Sensitivity to Endocrine Therapy test (SET) measures Sensitivity to Endocrine Therapy in all stages of HR+HER- breast cancer. The SET test is currently being used in prospective clinical trials. Delphi’s mission is to make the SET test available to breast cancer patients, maximize disease-free survival while minimizing toxicity, and avoid non-beneficial treatments.
To learn more, visit www.delphi-diagnostics.com.
Contact Delphi Diagnostics:
Delphi Diagnostics Inc.